|
|
|
|
|
CUSIP No. 293614103
|
|
13D
|
|
Page 16 of 23 Pages
|
Schedule 13D
Item 1.
Security and Issuer
.
This
Amendment No. 1 (Amendment No. 1) to the statement on Schedule 13D amends and supplements the statement on Schedule 13D originally filed on October 9, 2018 (the Original 13D) to the Common Stock, par value
$0.001 per share (the Common Stock), of Entasis Therapeutics Holdings Inc. (the Issuer). The address of the principal executive offices of the Issuer is 35 Gatehouse Drive, Waltham, Massachusetts 02451.
This Amendment No. 1 is being filed in connection with the acquisition by The Blackstone Group L.P. and certain of its affiliates
(Blackstone) of Clarus Ventures, LLC and certain of its affiliates (collectively, Clarus). On January 4, 2019, Blackstone integrated the Clarus business into Blackstone (the Clarus Integration). As a result
of such integration, Blackstone may be deemed to have become the beneficial owner of the securities beneficially owned by Clarus, including the securities of the Issuer.
Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Original 13D. Except as specifically
provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Original 13D.
Item 2.
Identity and
Background
.
This statement is being filed by:
(a) Clarus Lifesciences III, L.P. (the Fund);
(b) Clarus Ventures III GP, L.P. (Clarus GP), which is the sole general partner of the Fund;
(c) Blackstone Clarus III L.L.C., which is the sole general partner of Clarus GP, Blackstone Holdings II L.P., which is the sole member of
Blackstone Clarus III L.L.C., Blackstone Holdings I/II GP Inc., which is the sole general partner of Blackstone Holdings II L.P., The Blackstone Group L.P., which is the controlling shareholder of Blackstone Holdings I/II GP Inc., and Blackstone
Group Management L.L.C. (collectively, with Blackstone Clarus III L.L.C., Blackstone Holdings II L.P., Blackstone Holdings I/II GP Inc. and The Blackstone Group L.P., the Control Entities), which is the sole general partner of The
Blackstone Group L.P. and which is wholly-owned by Blackstones senior managing directors and controlled by its founder, Stephen A. Schwarzman; and
(d) Clarus Ventures III, LLC (Clarus GP LLC), and Robert Liptak, Nicholas Simon, Nicholas Galakatos, Dennis Henner and Kurt
Wheeler (together, the Managing Directors, and, collectively with Clarus GP LLC, the Clarus Persons). The Managing Directors are the members of Clarus GP LLC. Clarus GP LLC is the former general partner of Clarus GP.
The persons named in this Item 2 are referred to individually herein as a Reporting Person and collectively as the Reporting
Persons. The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13D as
Exhibit 99.1
(which is incorporated herein by reference), pursuant to which the
Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule
13d-1(k)
under the Act.
The address of the principal business office of the Fund, Clarus GP and each of the Clarus Persons is Clarus Ventures, 101 Main Street, Suite
1210, Cambridge, MA 02142. The address of the principal business office of each of the Control Entities and Mr. Schwarzman is c/o The Blackstone Group L.P., 345 Park Avenue, New York, NY 10154.